Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*.
| Characteristic | All (N=1062) |
Remdesivir (N=541) |
Placebo (N=521) |
|---|---|---|---|
| Age — yr | 58.9±15.0 | 58.6±14.6 | 59.2±15.4 |
| Male sex — no. (%) | 684 (64.4) | 352 (65.1) | 332 (63.7) |
| Race or ethnic group — no. (%)† | |||
| American Indian or Alaska Native | 7 (0.7) | 4 (0.7) | 3 (0.6) |
| Asian | 135 (12.7) | 79 (14.6) | 56 (10.7) |
| Black or African American | 226 (21.3) | 109 (20.1) | 117 (22.5) |
| White | 566 (53.3) | 279 (51.6) | 287 (55.1) |
| Hispanic or Latino — no. (%) | 250 (23.5) | 134 (24.8) | 116 (22.3) |
| Median time (IQR) from symptom onset to randomization — days‡ | 9 (6–12) | 9 (6–12) | 9 (7–13) |
| No. of coexisting conditions — no. /total no. (%)‡ | |||
| None | 194/1048 (18.5) | 97/531 (18.3) | 97/517 (18.8) |
| One | 275/1048 (26.2) | 138/531 (26.0) | 137/517 (26.5) |
| Two or more | 579/1048 (55.2) | 296/531 (55.7) | 283/517 (54.7) |
| Coexisting conditions — no./total no. (%) | |||
| Type 2 diabetes | 322/1051 (30.6) | 164/532 (30.8) | 158/519 (30.4) |
| Hypertension | 533/1051 (50.7) | 269/532 (50.6) | 264/519 (50.9) |
| Obesity | 476/1049 (45.4) | 242/531 (45.6) | 234/518 (45.2) |
| Score on ordinal scale — no. (%) | |||
| 4. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (Covid-19–related or otherwise) | 138 (13.0) | 75 (13.9) | 63 (12.1) |
| 5. Hospitalized, requiring supplemental oxygen | 435 (41.0) | 232 (42.9) | 203 (39.0) |
| 6. Hospitalized, receiving noninvasive ventilation or high-flow oxygen devices | 193 (18.2) | 95 (17.6) | 98 (18.8) |
| 7. Hospitalized, receiving invasive mechanical ventilation or ECMO | 285 (26.8) | 131 (24.2) | 154 (29.6) |
| Baseline score missing | 11 (1.0) | 8 (1.5) | 3 (0.6) |
*
Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. IQR denotes interquartile range, and ECMO extracorporeal membrane oxygenation. The full table of baseline characteristics is available in the Supplementary Appendix.
†
Race and ethnic group were reported by the patients. The number of patients in other races and ethnic groups are listed in Table S1 in the Supplementary Appendix.
‡
Data on symptom onset were missing for 3 patients; data on coexisting conditions were missing for 11 patients and were incomplete for 3 patients.